RCAR - RenovaCare, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
5.04
+0.11 (+2.23%)
As of 11:24AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close4.93
Open5.05
Bid0.00 x 0
Ask0.00 x 0
Day's Range4.93 - 5.08
52 Week Range2.20 - 6.35
Volume53,691
Avg. Volume43,929
Market Cap383.773M
Beta2.27
PE Ratio (TTM)N/A
EPS (TTM)-0.04
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • RenovaCare 2018 Outlook and Shareholder Update from the CEO
    Business Wire7 days ago

    RenovaCare 2018 Outlook and Shareholder Update from the CEO

    RenovaCare, Inc., , developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, is pleased to provide its outlook for 2018, which includes a shareholder update on the Company’s plans to advance its products towards market.

  • Business Wire8 days ago

    RenovaCare Comments on Recent Market Activity

    RenovaCare, Inc. , developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced that on January 3rd, 2018, OTC Markets Group Inc.

  • Business Wire3 months ago

    RenovaCare Announces Successful Closing of Financing

    RenovaCare, Inc., , developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced the closing of its previously announced registered direct offering of 915,000 shares of its common stock at a an offering price of $2.50 per share and its concurrent private placement of common stock purchase warrants ...

  • Business Wire3 months ago

    RenovaCare, Inc. Closes Registered Direct Offering and Concurrent Private Placement

    RenovaCare, Inc., , developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately 915,000 shares of common stock in a registered direct offering and common stock purchase warrants in a concurrent ...

  • Peer-Reviewed Publication Validates RenovaCare Approach to Rapidly-Processing Stem Cells for Burns and Wounds
    Business Wire6 months ago

    Peer-Reviewed Publication Validates RenovaCare Approach to Rapidly-Processing Stem Cells for Burns and Wounds

    RenovaCare, Inc., , has announced that its approach to isolating a patient’s own stem cells for subsequent spray onto burns and wounds has been validated by researchers in ‘Differentiation’, a leading peer-reviewed scientific publication.

  • Outcomes of Burn Patients Treated with Cell Spray Technology Behind RenovaCare SkinGun™ Published in Prestigious Medical Journal
    Business Wire9 months ago

    Outcomes of Burn Patients Treated with Cell Spray Technology Behind RenovaCare SkinGun™ Published in Prestigious Medical Journal

    RenovaCare, Inc., , highlighted an analysis of treatment results on a variety of wide-area and severe burn injuries published in Burns, the peer-reviewed Journal of the International Society for Burn Injuries.

  • RenovaCare: 2017 Shareholder Update
    Business Wirelast year

    RenovaCare: 2017 Shareholder Update

    RenovaCare, Inc., , developer of the patented CellMist™ and SkinGun™ technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today issued its beginning of the year 2017 shareholder update.